Chapter 36

  1. Afshari A, Wetterslev J, Brok J, et al. 2008. Antithrombin III for critically ill patients. Cochrane Database Syst Rev CD005370.
  2. Aird WC. 2003. The hematologic system as a marker of organ dysfunction in sepsis. Mayo Clin Proc 78:869-881.
  3. Aird WC. 2005. Sepsis and coagulation. Crit Care Clin 21:417-431.
  4. Akira S, Takeda K. 2004. Toll-like receptor signalling. Nat Rev Immunol 4:499-511.
  5. Aldrich J. 2009. Shock fluids and fluid challenge, pp 276-280. In Silverstein DC, Hopper K (eds): Small animal critical care medicine. Saunders Elsevier, St Louis.
  6. Andersen SK, Gjedsted J, Christiansen C, et al. 2004. The roles of insulin and hyperglycemia in sepsis pathogenesis. J Leukoc Biol 75:413-421.
  7. Andersson U, Wang H, Palmblad K. 2000. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 192:565-5570.
  8. Angstwurm MW, Schottdorf J, Schopophl J, et al. 1999. Selenium replacement in patients with severe systemic inflammatory response syndrome improves clinical outcome. Crit Care Med 27:1807-1813.
  9. Annane D. 2000. Effects of the combination of hydrocortisone (HC)-fludrocortisone (FC) on mortality in septic shock (abstract A63). Crit Care Med 28:A46
  10. Annane D. 2008. Adrenal insufficiency in sepsis. Curr Pharm Des 14:1882-1886.
  11. Annane D, Bellissant E, Bollaert PE, et al. 2009. Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review. JAMA 301:2362-2375.
  12. Annane D, Sebille V, Charpentier C, et al. 2002. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288:862-871.
  13. Anonymous. 1992. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20:864-874.
  14. Bateman RM, Sharpe MD, Ellis CG. 2003. Bench-to-bedside review: microvascular dysfunction in sepsis—hemodynamics, oxygen transport, and nitric oxide. Crit Care 7:359-373.
  15. Bellissant E, Annane D. 2000. Effect of hydrocortisone on phenylephrine-mean arterial pressure dose-response relationship in septic shock. Clin Pharmacol Ther 68:293-303.
  16. Bentley AM, Otto CM, Shofer FS. 2007. Comparison of dogs with septic peritonitis: 1988-1993 versus 1999-2003. J Vet Emerg Crit Care 17:391-398.
  17. Bernard GR. 2003. Drotrecogin alfa (activated) (recombinant human activated protein C) for the treatment of severe sepsis. Crit Care Med 31:S85-S93.
  18. Bernard GR, Margolis BD, Shanies HM, et al. 2004. Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis. Chest 125:2206-2216.
  19. Bernard GR, Vincent JL, Laterre PF, et al. 2001. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699-709.
  20. Bersenas AM, Mathews KA, Allen DG, et al. 2005. Effects of ranitidine, famotidine, pantoprazole, and omeprazole on intragastric pH in dogs. Am J Vet Res 66:425-431.
  21. Bollaert PE, Charpentier C, Levy B, et al. 1998. Reversal of late septic shock with physiologic doses of hydrocortisone. Crit Care Med 26:645-650.
  22. Bonczynski JJ, Ludwig LL, Barton LJ, et al. 2003. Comparison of peritoneal fluid and peripheral blood pH, bicarbonate, glucose, and lactate concentration as a diagnostic tool for septic peritonitis in dogs and cats. Vet Surg 32:161-166.
  23. Bone RC, Grodzin CJ, Balk RA. 1997. Sepsis: a new hypothesis for pathogenesis of the disease process. Chest 112:235-243.
  24. Brady CA, Otto CM. 2001. Systemic inflammatory response syndrome, sepsis, and multiple organ dysfunction. Vet Clin North Am Small Anim Pract 31:1147-1162.
  25. Brady CA, Otto CM, Van Winkle TJ, et al. 2000. Severe sepsis in cats: 29 cases (1986-1998). J Am Vet Med Assoc 217:531-535.
  26. Buras JA, Holzmann B, Sitkovsky M. 2005. Animal models of sepsis: setting the stage. Nature Rev Drug Discov 4:854-865.
  27. Burkitt JM, Haskins SC, Nelson RW, et al. 2007. Relative adrenal insufficiency in dogs with sepsis. J Vet Intern Med 21:226-231.
  28. 27a. Butler AL, Campbell VL. 2010. Assessment of oxygen transport and utilization in dogs with naturally occurring sepsis. J Am Vet Med Assoc 237:167-173.
  29. Camacho AT, Pallas E, Gestal JJ, et al. 2002. Babesia canis infection in a splenectomized dog. Bull Soc Pathol Exot 95:17-19.
  30. Ceron JJ, Eckersall PD, Martynez-Subiela S. 2005. Acute phase proteins in dogs and cats: current knowledge and future perspectives. Vet Clin Pathol 34:85-99.
  31. Ceron JJ, Martinez-Subiela S, Ohno K, et al. 2008. A seven-point plan for acute phase protein interpretation in companion animals. Vet J 177:6-7.
  32. Chan, DL, Freeman LM, Rozanski EA, et al. 2002. Prevalence of hyperglycemia in cats presented to the emergency service. J Vet Emerg Crit Care 12:199.
  33. Chappell D, Westphal M, Jacob M. 2009. The impact of the glycocalyx on microcirculatory oxygen distribution in critical illness. Curr Opin Anaesthesiol 22:155-162.
  34. Chelazzi C, Consales G, De Gaudio AR. 2008. Sepsis associated encephalopathy. Curr Anaesth Crit Care 19:15-21.
  35. Christopher MM. 1989. Relation of endogenous Heinz bodies to disease and anemia in cats: 120 cases (1978-1987). J Am Vet Med Assoc 194:1089-1095.
  36. Christopher MM, White JG, Eaton JW. 1990. Erythrocyte pathology and mechanisms of Heinz body-mediated hemolysis in cats. Vet Pathol 27:299-310.
  37. Clayton SB, Mazur JE, Condren S, et al. 2006. Evaluation of an intensive insulin protocol for septic patients in a medical intensive care unit. Crit Care Med 34:2974-2978.
  38. Cohen J. 2009. Non-antibiotic strategies for sepsis. Clin Microbiol Infect 15:302-307.
  39. Consales G, De Gaudio AR. 2005. Sepsis associated encephalopathy. Minerva Anestesiol 71:39-52.
  40. Costello MF, Drobatz KJ, Aronson LR, et al. 2004. Underlying cause, pathophysiologic abnormalities, and response to treatment in cats with septic peritonitis: 51 cases (1990-2001). J Am Vet Med Assoc 225:897-902.
  41. Costello MF, Fletcher DJ, Silverstein DC, et al. 2006. Adrenal insufficiency in feline sepsis [poster]. 35th Critical Care Congress Society of Critical Care Medicine, San Francisco.
  42. Day KM, Haub N, Betts H, et al. 2008. Hyperglycemia is associated with morbidity in critically ill children with meningococcal sepsis. Pediatr Crit Care Med 9:636-640.
  43. De Backer D, Creteur J, Preiser JC, et al. 2002. Microvascular blood flow is altered in patients with sepsis. Am J Respir Crit Care Med 166:98-104.
  44. De Backer D, Donadello K, Favory R. 2009. Link between coagulation abnormalities and microcirculatory dysfunction in critically ill patients. Curr Opin Anaesthesiol 22:150-154.
  45. DeClue AE, Williams KJ, Sharp C, et al. 2009. Systemic response to low-dose endotoxin infusion in cats. Vet Immunol Immunopathol 132:167-174.
  46. 44a. Deitchel SJ, Kerl ME, Chang CH, et al. 2010. Age-associated changes to pathogen-associated molecular pattern-induced inflammatory mediator production in dogs. J Vet Emerg Crit Care 20:494-502.
  47. de Laforcade AM, Freeman LM, Shaw SP, et al. 2003. Hemostatic changes in dogs with naturally occurring sepsis. J Vet Intern Med 17:674-679.
  48. de Laforcade AM, Rozanski EA, Freeman LM, et al. 2008. Serial evaluation of protein C and antithrombin in dogs with sepsis. J Vet Intern Med 22:26-30.
  49. Dellinger RP. 2003. Inflammation and coagulation: implications for the septic patient. Clin Infect Dis 36:1259-1265.
  50. Dellinger RP, Levy MM, Carlet JM, et al. 2008. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 36:296-327.
  51. Dhainaut JF, Laterre PF, Janes JM, et al. 2003. Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial. Intensive Care Med 29:894-903.
  52. Di Giantomasso D, May CN, Bellomo R. 2003. Vital organ blood flow during hyperdynamic sepsis. Chest 124:1053-1059.
  53. Dimmitt R. 1991. Clinical experience with cross-protective anti-endotoxin antiserum in dogs with parvoviral enteritis. Canine Pract 16:23-26.
  54. Docke WD, Randow F, Syrbe U, et al. 1997. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med 3:678-681.
  55. Dorsount MF, Kilbourn RG, Hartley CJ, et al. 2000. Effects of N-methyl-L-arginine on cardiac and regional blood flow in a dog endotoxin shock model. J Crit Care 15:22-29.
  56. Draisma A, Bemelmans R, van der Hoeven JG, et al. 2009. Microcirculation and vascular reactivity during endotoxemia and endotoxin tolerance in humans. Shock 31:581-585.
  57. Drazenovic R, Samsel RW, Wylam ME, et al. 1992. Regulation of perfused capillary density in canine intestinal mucosa during endotoxemia. J Appl Physiol 72:259-265.
  58. Dronge AS, Perkal MF, Kancir S, et al. 2006. Long-term glycemic control and postoperative infectious complications. Arch Surg 141:375-380.
  59. 56a. Duffy AL, Olea-Popelka FJ, Eucher J, et al. 2010. Serum concentrations of monocyte chemoattractant protein-1 in healthy and critically ill dogs. Vet Clin Pathol 39:302-305.
  60. Dunser MW, Mayr AJ, Ulmer H, et al. 2003. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation 107:2313-2319.
  61. Errington ML, Rocha e Silva. 1971. The secretion and clearance of vasopressin during the development of irreversible haemorrhagic shock. J Physiol 217:43P-45P.
  62. Estrin MA, Wehausen CE, Jessen CR, et al. 2006. Disseminated intravascular coagulation in cats. J Vet Intern Med 20:1334-1339.
  63. Farquhar I, Martin CM, Lam C, et al. 1996. Decreased capillary density in vivo in bowel mucosa of rats with normotensive sepsis. J Surg Res 61:190-196.
  64. Fein AM, Calalang-Colucci MG. 2000. Acute lung injury and acute respiratory distress syndrome in sepsis and septic shock. Crit Care Clin 16:289-317.
  65. Fink MP. 2003. Intestinal epithelial hyperpermeability: update on the pathogenesis of gut mucosal barrier dysfunction in critical illness. Curr Opin Crit Care 9:143-151.
  66. Fitch SJ, Gossage JR. 2002. Optimal management of septic shock. Postgrad Med 111:53-65.
  67. Flierl MA, Rittirsch D, Huber-Lang MS, et al. 2008. Molecular events in the cardiomyopathy of sepsis. Mol Med 14:327-336.
  68. Flierl MA, Schreiber H, Huber-Lang MS. 2006. The role of complement, C5a and its receptors in sepsis and multiorgan dysfunction syndrome. J Invest Surg 19:255-265.
  69. Fries M, Weil MH, Sun S, et al. 2006. Increases in tissue Pco2 during circulatory shock reflect selective decreases in capillary blood flow. Crit Care Med 34:446-452.
  70. Galley HF, Howdle PD, Walker BE, et al. 1997. The effects of intravenous antioxidants in patients with septic shock. Free Radic Biol Med 23:768-774.
  71. Gando S, Nanzaki S, Sasaki S, et al. 1998. Activation of the extrinsic coagulation pathway in patients with severe sepsis and septic shock. Crit Care Med 26:2005-2009.
  72. 68a. Gebhardt C, Hirschberger J, Rau S, et al. 2009. Use of C-reactive protein to predict outcome in dogs with systemic inflammatory response syndrome or sepsis. J Vet Emerg Crit Care 19:450-458.
  73. Gibson BR, Galiatsatos P, Rabiee A, et al. 2009. Intensive insulin therapy confers a similar survival benefit in the burn intensive care unit to the surgical intensive care unit. Surgery 146:922-930.
  74. Gimson AE. 1987. Hepatic dysfunction during bacterial sepsis. Intensive Care Med 13:162-166.
  75. Giroir BP, Scannon PJ, Levin M. 2001. Bactericidal/permeability-increasing protein—lessons learned from the phase III, randomized, clinical trial of rBPI21 for adjunctive treatment of children with severe meningococcemia. Crit Care Med 29:S130-S135.
  76. Greenfield CL, Walshaw R. 1987. Open peritoneal drainage for treatment of contaminated peritoneal cavity and septic peritonitis in dogs and cats: 24 cases (1980-1986). J Am Vet Med Assoc 191:100-105.
  77. Greiner M, Wolf G, Hartmann K. 2008. A retrospective study of the clinical presentation of 140 dogs and 39 cats with bacteraemia. J Small Anim Pract 49:378-383.
  78. Guzman JA, Rosado AE, Kruse JA. 2003. Vasopressin vs norepinephrine in endotoxic shock: systemic, renal, and splanchnic hemodynamic and oxygen transport effects. J Appl Physiol 95:803-809.
  79. Hardie EM. 1995. Life-threatening bacterial infection. Compend Cont Educ Pract Vet 17:290-302.
  80. Hardie EM. 2000. Therapeutic management of sepsis, pp 272-275. In Bonagura JD (ed): Kirk's current veterinary therapy XIII: small animal practice. WB Saunders, Philadelphia.
  81. Hauptman JG, Walshaw R, Olivier NB. 1997. Evaluation of the sensitivity and specificity of diagnostic criteria for sepsis in dogs. Vet Surg 26:393-397.
  82. Hirasawa H, Oda S, Nakamura M. 2009. Blood glucose control in patients with severe sepsis and septic shock. World J Gastroenterol 15:4132-4136.
  83. Hochreiter M, Kohler T, Schweiger AM, et al. 2009. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Crit Care 13:R83.
  84. Hodgson JC. 2006. Endotoxin and mammalian host responses during experimental disease. J Comp Pathol 135:157-175.
  85. Hoffmann JJ. 2009. Neutrophil CD64: a diagnostic marker for infection and sepsis. Clin Chem Lab Med 47:903-916.
  86. Hosgood G, Salisbury SK. 1988. Generalized peritonitis in dogs: 50 cases (1975-1986). J Am Vet Med Assoc 193:1448-1450.
  87. Hotchkiss RS, Karl IE. 2003. The pathophysiology and treatment of sepsis. N Engl J Med 348:138-150.
  88. Hotchkiss RS, Tinsley KW, Swanson PE, et al. 2002. Endothelial cell apoptosis in sepsis. Crit Care Med 30:S225-S228.
  89. Hunter JD, Doddi M. 2010. Sepsis and the heart. Br J Anaesth 104:3-11.
  90. Hurcombe SD, Toribio RE, Slovis N, et al. 2008. Blood arginine vasopressin, adrenocorticotropin hormone, and cortisol concentrations at admission in septic and critically ill foals and their association with survival. J Vet Intern Med 22:639-647.
  91. Hurley J, Levin J. 1999. The relevance of endotoxin detection in sepsis, pp 841-854. In Brade H, Opal SM, Vogel SN, et al (eds): Endotoxin in health and disease. Marcel Dekker, New York.
  92. Ince C. 2005. The microcirculation is the motor of sepsis. Crit Care 9(Suppl 4):S13-S19.
  93. Jacobson LS. 2006. The South African form of severe and complicated canine babesiosis: clinical advances 1994-2004. Vet Parasitol 138:126-139.
  94. 89a. Jessen LR, Winberg B, Kjelgaard-Hansen M, et al. 2010. Thrombin-activatable fibrinolysis inhibitor activity in healthy and diseased dogs. Vet Clin Pathol 39:296-301.
  95. Juneja R, Roudebush CP, Nasraway SA, et al. 2009. Computerized intensive insulin dosing can mitigate hypoglycemia and achieve tight glycemic control when glucose measurement is performed frequently and on time. Crit Care 13:R163.
  96. 90a. Kenny EM, Rozanski EA, Rush JE, et al. 2010. Association between outcome and organ system dysfunction in dogs with sepsis: 114 cases (2003-2007). J Am Vet Med Assoc 236:83-87.
  97. King LG. 1994. Postoperative complications and prognostic indicators in dogs and cats with septic peritonitis: 23 cases (1989-1992). J Am Vet Med Assoc 204, 407-414.
  98. Kitchens CS. 2009. Thrombocytopenia and thrombosis in disseminated intravascular coagulation (DIC). Hematol Am Soc Hematol Educ Program 2009:240-246.
  99. Klijn E, Den Uil CA, Bakker J, et al. 2008. The heterogeneity of the microcirculation in critical illness. Clin Chest Med 29:643-654, viii.
  100. Kopterides P, Falagas ME. 2009. Statins for sepsis: a critical and updated review. Clin Microbiol Infect 15:325-334.
  101. Landry DW, Levin HR, Gallant EM, et al. 1997. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 95:1122-1125.
  102. Leon CG, Tory R, Jia J, et al. 2008. Discovery and development of Toll-like receptor 4 (TLR4) antagonists: a new paradigm for treating sepsis and other diseases. Pharm Res 25:1751-1761.
  103. Levi M. 2008. The coagulant response in sepsis. Clin Chest Med 29:627-642, viii.
  104. Levy MM, Fink MP, Marshall JC, et al. 2003. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 29:530-538.
  105. Lewis KS, Kane-Gill SL, Bobek MB, et al. 2004. Intensive insulin therapy for critically ill patients. Ann Pharmacother 38:1243-1251.
  106. Lien E, Ingalls RR. 2002. Toll-like receptors. Crit Care Med 30:S1-11.
  107. Linder A, Christensson B, Herwald H, et al. 2009. Heparin-binding protein: an early marker of circulatory failure in sepsis. Clin Infect Dis 49:1044-1050.
  108. Lopez A, Lorente JA, Steingrub J, et al. 2004. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 32:21-30.
  109. Lotze MT, Zeh HJ, Rubartelli A, et al. 2007. The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol Rev 220:60-81.
  110. Luce JM. 1998. Acute lung injury and the acute respiratory distress syndrome. Crit Care Med 26:369-376.
  111. Luckner G, Dunser MW, Jochberger S, et al. 2005. Arginine vasopressin in 316 patients with advanced vasodilatory shock. Crit Care Med 33:2659-2666.
  112. Madden RM, Ward M, Marlar RA. 1989. Protein C activity levels in endotoxin-induced disseminated intravascular coagulation in a dog model. Thromb Res 55:297-307.
  113. Malay MB, Ashton RC, Jr., Landry DW, et al. 1999. Low-dose vasopressin in the treatment of vasodilatory septic shock. J Trauma 47:699-703.
  114. Manglik S, Flores E, Lubarsky L, et al. 2003. Glucocorticoid insufficiency in patients who present to the hospital with severe sepsis: a prospective clinical trial. Crit Care Med 31:1668-1675.
  115. Mann HJ, Short MA, Schlichting DE. 2009. Protein C in critical illness. Am J Health Syst Pharm 66:1089-1096.
  116. Mantione NL, Otto CM. 2005. Characterization of the use of antiemetic agents in dogs with parvoviral enteritis treated at a veterinary teaching hospital: 77 cases (1997-2000). J Am Vet Med Assoc 227:1787-1793.
  117. Marik PE, Pastores SM, Annane D, et al. 2008. Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine. Crit Care Med 36:1937-1949.
  118. Marik PE, Raghavan M. 2004. Stress-hyperglycemia, insulin and immunomodulation in sepsis. Intensive Care Med 30:748-756.
  119. Marshall JC. 2003. Such stuff as dreams are made on: mediator-directed therapy in sepsis. Nature Rev Drug Discov 2:391-405.
  120. Marshall JC, Walker PM, Foster DM, et al. 2002. Measurement of endotoxin activity in critically ill patients using whole blood neutrophil dependent chemiluminescence. Crit Care 6:342-348.
  121. Marti-Carvajal A, Salanti G, Cardona AF. 2008. Human recombinant activated protein C for severe sepsis. Cochrane Database Syst Rev CD004388.
  122. Martin LG, Groman RP. 2004. Relative adrenal insufficiency in critical illness. J Vet Emerg Crit Care 14:149-157.
  123. Martin LG, Groman RP, Fletcher DJ, et al. 2008. Pituitary-adrenal function in dogs with acute critical illness. J Am Vet Med Assoc 233:87-95.
  124. Martinez-Albarran M, Perez-Molina JJ, et al. 2009. Procalcitonin and C-reactive protein serum levels as markers of infection in a pediatric population with febrile neutropenia and cancer. Pediatr Hematol Oncol 26:414-425.
  125. Maury E, Barakett V, Blanchard H, et al. 1998. Circulating endotoxin during initial antibiotic treatment of severe gram-negative bacteremic infections. J Infect Dis 178:270-273.
  126. Mazzaferro EM, Rudloff E, Kirby R. 2002. The role of albumin replacement in the critically ill veterinary patient. J Vet Emerg Crit Care 12:113-124.
  127. McKenzie HC, Furr MO. 2001. Equine neonatal sepsis: the pathophysiology of severe inflammation and infection. Compend Cont Educ Pract Vet 23:661-671.
  128. Mesotten D, Swinnen JV, Vanderhoydonc F, et al. 2004. Contribution of circulating lipids to the improved outcome of critical illness by glycemic control with intensive insulin therapy. J Clin Endocrinol Metab 89:219-226.
  129. Metz DC. 2005. Preventing the gastrointestinal consequences of stress-related mucosal disease. Curr Med Res Opin 21:11-18.
  130. Metz J, McGrath KM, Copperchini ML, et al. 1995. Appropriateness of transfusions of red cells, platelets and fresh frozen plasma. An audit in a tertiary care teaching hospital. Med J Aust 162:572-577.
  131. Metzler M, Schuster DP, the Phase II Pafase ARDS Prevention Group. 1999. Recombinant platelet activating factor acetylhydrolase (rPAF-AH) improves organ dysfunction and survival in patients with severe sepsis (abstract). Crit Care Med 29:A19.
  132. Minneci PC, Deans KJ, Banks SM, et al. 2004. Differing effects of epinephrine, norepinephrine, and vasopressin on survival in a canine model of septic shock. Am J Physiol Heart Circ Physiol 287:H2545-H2554.
  133. Mitaka C, Hirata Y, Masaki Y, et al. 2000. S-Methylisothiourea sulfate improves renal, but not hepatic dysfunction in canine endotoxic shock model. Intensive Care Med 26:117-124.
  134. Mitaka C, Hirata Y, Yokoyama K, et al. 1999. Improvement of renal dysfunction in dogs with endotoxemia by a nonselective endothelin receptor antagonist. Crit Care Med 27:146-153.
  135. Mitaka C, Hirata Y, Yokoyama K, et al. 2001. L-Canavanine, a selective inhibitor of inducible NO synthase, increases plasma endothelin-1 concentrations in dogs with endotoxic shock. J Crit Care 16:17-23.
  136. Miyamoto T, Fujinaga T, Yamashita K, et al. 1996. Changes of serum cytokine activities and other parameters in dogs with experimentally induced endotoxic shock. Jpn J Vet Res 44:107-118.
  137. Moeniralam HS, Bemelman WA, Romijn JA, et al. 1997. Origin of endotoxemia influences the metabolic response to endotoxin in dogs. J Surg Res 73:47-53.
  138. Morales D, Madigan J, Cullinane S, et al. 1999. Reversal by vasopressin of intractable hypotension in the late phase of hemorrhagic shock. Circulation 100:226-229.
  139. Morresey PR. 2001. Synthesis of proinflammatory mediators in endotoxemia. Compend Contin Educ Pract Vet 23:829-852.
  140. Morresey PR. 2001. Therapeutic intervention strategies in endotoxemia. Compend Contin Educ Pract Vet 23:925-930.
  141. Moseley RH. 2004. Sepsis and cholestasis. Clin Liver Dis 8:83-94.
  142. Mutunga M, Fulton B, Bullock R, et al. 2001. Circulating endothelial cells in patients with septic shock. Am J Respir Crit Care Med 163:195-200.
  143. Natanson C. 1990. Studies using a canine model to investigate the cardiovascular abnormality of and potential therapies for septic shock. Clin Res 38:206-214.
  144. Neyrinck AP, Liu KD, Howard JP, et al. 2009. Protective mechanisms of activated protein C in severe inflammatory disorders. Br J Pharmacol 158:1034-1047.
  145. Oh JS, Kim SU, Oh YM, et al. 2009. The usefulness of the semiquantitative procalcitonin test kit as a guideline for starting antibiotic administration. Am J Emerg Med 27:859-863.
  146. Okano S, Tagawa M, Takase K. 1998. Relationship of the blood endotoxin concentration and prognosis in dog pyometra. J Vet Med Sci 60:1265-1267.
  147. Okano S, Yoshida M, Fukushima U, et al. 2002. Usefulness of systemic inflammatory response syndrome criteria as an index for prognosis judgment. Vet Rec 150:245-246.
  148. O’Neill LAJ. 2005. Immunity's early-warning system. Sci Am 292:38-45.
  149. Opal SM, Fisher CJ, Dhainaut JF, et al. 1997. Confirmatory interleukin 1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. Crit Care Med 25:1115-1124.
  150. Otto CM, Jackson CB, Rogell E, et al. 2001. Recombinant bactericidal/permeability increasing protein (rBPI21) for treatment of parvovirus enteritis: a randomized, double-blinded, placebo-controlled clinical trial. J Vet Intern Med 15:355-360.
  151. Otto CM, Rieser TM, Brooks MB, et al. 2000. Evidence of hypercoagulability in dogs with parvoviral enteritis. J Am Vet Med Assoc 217:1500-1504.
  152. Panciera DL, Ritchey JW, Ward DL. 2003. Endotoxin-induced nonthyroidal illness in dogs. Am J Vet Res 64:229-234.
  153. 146a. Papich M. 2002. Saunders Handbook of Veterinary Drugs, ed 2. Saunders-Elsevier, St Louis.
  154. Parent C, King LG, Walker LM, et al. 1996. Clinical and clinicopathologic findings in dogs with acute respiratory distress syndrome: 19 cases (1985-1993). J Am Vet Med Assoc 208:1419-1427.
  155. Parsons KJ, Owen LJ, Lee K, et al. 2009. A retrospective study of surgically treated cases of septic peritonitis in the cat (2000-2007). J Small Anim Pract 50:518-524.
  156. Patel BM, Chittock DR, Russell JA, et al. 2002. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 96:576-582.
  157. Perkins ND. 2007. Integrating cell-signalling pathways with NF-κB and IKK function. Nat Rev Mol Cell Biol 8:49-62.
  158. Pinsky MR, Rico P. 2000. Cardiac contractility is not depressed in early canine endotoxic shock. Am J Respir Crit Care Med 161:1087-1093.
  159. Preiser JC, Zhang H, Vray B, et al. 2001. Time course of inducible nitric oxide synthase activity following endotoxin administration in dogs. Nitric Oxide 5:208-211.
  160. Prigent H, Maxime V, Annane D. 2004. Clinical review: corticotherapy in sepsis. Crit Care 8:122-129.
  161. Prigent H, Maxime V, Annane D. 2004. Science review: mechanisms of impaired adrenal function in sepsis and molecular actions of glucocorticoids. Crit Care 8:243-252.
  162. Prittie JE, Barton LJ, Peterson ME, et al. 2003. Hypothalamo-pituitary-adrenal axis function in critically ill cats, p 771. Proceedings of the 9th International Veterinary Emergency and Critical Care Symposium, Sept 9-13, New Orleans.
  163. Purvis D, Kirby R. 1994. Systemic inflammatory response syndrome: septic shock. Vet Clin North Am: Small Anim Pract 24:1225-1247.
  164. Rangel-Frausto MS, Pittet D, Costigan M, et al. 1995. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 273:117-123.
  165. Rau S, Kohn B, Richter C, et al. 2007. Plasma interleukin-6 response is predictive for severity and mortality in canine systemic inflammatory response syndrome and sepsis. Vet Clin Pathol 36:253-260.
  166. Ray CC, Callahan-Clark J, Beckel N, et al. 2009. The prevalence and significance of hyperglycemia in hospitalized cats. J Vet Emerg Crit Care 19:347-351.
  167. Rewerts JM, McCaw DL, Cohn LA, et al. 1998. Recombinant human granulocyte colony-stimulating factor for treatment of puppies with neutropenia secondary to canine parvovirus infection. J Am Vet Med Assoc 213:991-992.
  168. Riedemann NC, Guo RF, Ward PA, 2003. Novel strategies for the treatment of sepsis. Nature Med 9:517-524. Available at http://www.nature.com/nm/journal/v9/n5/fig_tab/nm0503-517_F2.html. Accessed 5/6/10.
  169. Rivers E, Nguyen B, Havstad S, et al. 2001. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345:1368-1377.
  170. Rivers EP, Coba V, Whitmill M. 2008. Early goal-directed therapy in severe sepsis and septic shock: a contemporary review of the literature. Curr Opin Anaesthesiol 21:128-140.
  171. 163a. Rogers CL, Rozanski EA. 2010. Von WIllebrand factor concentration in dogs with sepsis. J Vet Intern Med 24:229-230.
  172. Rothwell PM, Udwadia ZF, Lawler PG. 1991. Cortisol response to corticotropin and survival in septic shock. Lancet 337:582-583.
  173. Ruaux CG. 2000. Pathophysiology of organ failure in severe acute pancreatitis in dogs. Compend Cont Educ Pract Vet 22:531-542.
  174. Rudiger A, Singer M. 2007. Mechanisms of sepsis-induced cardiac dysfunction. Crit Care Med 35:1599-1608.
  175. Ruggiero MS. 2008. Effects of vasopressin in septic shock. AACN Adv Crit Care 19:281-287.
  176. Russell JA, Walley KR, Gordon AC, et al. 2009. Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Crit Care Med 37:811-818.
  177. Ruthrauff CM, Smith J, Glerum L. 2009. Primary bacterial septic peritonitis in cats: 13 cases. J Am Anim Hosp Assoc 45:268-276.
  178. Sakaue Y, Nezu Y, Yanagisawa S, et al. 2005. Effects of continuous low-dose infusion of lipopolysaccharide on expression of E-selectin and intercellular adhesion molecule-1 messenger RNA and neutrophil accumulation in specific organs in dogs. Am J Vet Res 66:1259-1266.
  179. Sakr Y, Dubois MJ, De Backer D, et al. 2004. Persistent microcirculatory alterations are associated with organ failure and death in patients with septic shock. Crit Care Med 32:1825-1831.
  180. Schouten M, Wiersinga WJ, Levi M, et al. 2008. Inflammation, endothelium, and coagulation in sepsis. J Leukoc Biol 83:536-545.
  181. Schrier RW, Wang W. 2004. Acute renal failure and sepsis. N Engl J Med 351:159-169.
  182. Schroeder S, Wichers M, Klingmuller D, et al. 2001. The hypothalamic-pituitary-adrenal axis of patients with severe sepsis: altered response to corticotropin-releasing hormone. Crit Care Med 29:310-316.
  183. Segev G, Klement E, Aroch I. 2006. Toxic neutrophils in cats: clinical and clinicopathologic features, and disease prevalence and outcome—a retrospective case control study. J Vet Intern Med 20:20-31.
  184. Seilenkamper, AW, Ellis CG, Kvietys P. 2002. The microcirculation in sepsis, pp191-202. In Evans TW, Fink MP (eds): Mechanisms of organ dysfunction in critical illness, ed 1. Springer, New York.
  185. Sganga G, Siegel JH, Brown G, et al. 1985. Reprioritization of hepatic plasma protein release in trauma and sepsis. Arch Surg 120:187-199.
  186. Shapiro NI, Trzeciak S, Hollander JE, et al. 2009. A prospective, multicenter derivation of a biomarker panel to assess risk of organ dysfunction, shock, and death in emergency department patients with suspected sepsis. Crit Care Med 37:96-104.
  187. 178a. Sharp CR, DeClue AE, Haak CE, et al. 2010. Evaluation of the anti-endotoxin effects of polymyxin B in a feline model of endotoxemia. J Fel Med Surg 12:278-285.
  188. Shorr AF, Bernard GR, Dhainaut JF, et al. 2006. Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome. Crit Care 10:R92.
  189. Siegel JP. 2002. Assessing the use of activated protein C in the treatment of severe sepsis. N Engl J Med 347:1030-1034.
  190. Silverstein DC. 2009. Daily intravenous fluid therapy, pp271-275. In Silverstein DC, Hopper K, (eds). Small animal critical care medicine. Saunders Elsevier, St Louis.
  191. Silverstein DC. 2009. Vasopressin, pp 759-762. In Silverstein DC, Hopper K, (eds): Small animal critical care medicine. Saunders Elsevier, St Louis.
  192. 182a. Silverstein DC, Montealegre C, Shofer FS, et al. 2009. The association between vascular endothelial growth factor levels and clinically evident peripheral edema in dogs with systemic inflammatory response syndrome. J Vet Emerg Crit Care 19:459-466.
  193. Silverstein DC, Pruett-Saratan A, Drobatz KJ. 2009. Measurements of microvascular perfusion in healthy anesthetized dogs using orthogonal polarization spectral imaging. J Vet Emerg Crit Care (San Antonio) 19:579-587.
  194. Silverstein DC, Waddell LS, Drobatz KJ, et al. 2007. Vasopressin therapy in dogs with dopamine-resistant hypotension and vasodilatory shock. J Vet Emerg Crit Care 17:399-408.
  195. Simmons JP, Wohl JS. 2009. Vasoactive catecholamines, pp 756-758. In Silverstein DC, Hopper K (eds): Small animal critical care medicine. Saunders Elsevier, St Louis.
  196. Sisson D, Thomas WP. 1984. Endocarditis of the aortic valve in the dog. J Am Vet Med Assoc 184:570-577.
  197. Soni A, Pepper GM, Wyrwinski PM, et al. 1995. Adrenal insufficiency occurring during septic shock: incidence, outcome, and relationship to peripheral cytokine levels. Am J Med 98:266-271.
  198. 187a. Sorenmo KU, Harwood LP, King LG, et al. 2010. Case-control study to evaluate risk factors for the development of sepsis (neutropenia and fever) in dogs receiving chemotherapy. J Am Vet Med Assoc 236:650-656.
  199. Spates ST, Cullen JJ, Ephgrave KS, et al. 1998. Effect of endotoxin on canine colonic motility and transit. J Gastrointest Surg 2:391-398.
  200. Spronk PE, Zandstra DF, Ince C. 2004. Bench-to-bedside review: sepsis is a disease of the microcirculation. Crit Care 8:462-468.
  201. Stollman N, Metz DC. 2005. Pathophysiology and prophylaxis of stress ulcer in intensive care unit patients. J Crit Care 20:35-45.
  202. Strassburg CP. 2003. Gastrointestinal disorders of the critically ill. Shock liver. Best Pract Res Clin Gastroenterol 17:369-381.
  203. Syring RS, Otto CM, Drobatz KJ. 2001. Hyperglycemia in dogs and cats with head trauma: 122 cases (1997-1999). J Am Vet Med Assoc 218:1124-1129.
  204. Taboada J, Meyer DJ. 1989. Cholestasis associated with extrahepatic bacterial infection in five dogs. J Vet Intern Med 3:216-221.
  205. Terblanche M, Almog Y, Rosenson RS, et al. 2007. Statins and sepsis: multiple modifications at multiple levels. Lancet Infect Dis 7:358-368.
  206. Thomas DD, Ridnour LA, Isenberg JS, et al. 2008. The chemical biology of nitric oxide: Implications in cellular signaling. Free Radical Biol Med 45:18-31.
  207. Tidswell M, Tillis W, LaRosa SP, et al. 2010. Phase 2 trial of eritoran tetrasodium (E5564), a Toll-like receptor 4 antagonist, in patients with severe sepsis. Crit Care Med 38:72-83.
  208. Tizard IR. 2000. Veterinary immunology, an introduction, ed 6. WB Saunders, Philadelphia.
  209. Tleyjeh IM, Kashour T, Hakim FA, et al. 2009. Statins for the prevention and treatment of infections: a systematic review and meta-analysis. Arch Intern Med 169:1658-1667.
  210. Torre DM, deLaforcade AM, Chan DL. 2007. Incidence and clinical relevance of hyperglycemia in critically ill dogs. J Vet Intern Med 21:971-975.
  211. Trzeciak S, Dellinger RP, Parrillo JE, et al. 2007. Early microcirculatory perfusion derangements in patients with severe sepsis and septic shock: relationship to hemodynamics, oxygen transport, and survival. Ann Emerg Med 49:88-98, 98.
  212. Trzeciak S, McCoy JV, Phillip DR, et al. 2008. Early increases in microcirculatory perfusion during protocol-directed resuscitation are associated with reduced multi-organ failure at 24 h in patients with sepsis. Intensive Care Med 34:2210-2217.
  213. Tscuhiya R, Kyotani K, Scott MA, et al. 1999. Role of platelet activating factor in development of thrombocytopenia and neutropenia in dogs with endotoxemia. Am J Vet Res 60:216-221.
  214. Usui M, Hanamura N, Hayashi T, et al. 1998. Molecular cloning, expression and tissue distribution of canine lipopolysaccharide (LPS)-binding protein. Biochim Biophys Acta 1397:202-212.
  215. Van Cromphaut SJ, Vanhorebeek I, Van den BG. 2008. Glucose metabolism and insulin resistance in sepsis. Curr Pharm Des 14:1887-1899.
  216. Van den BG, Wilmer A, Hermans G, et al. 2006. Intensive insulin therapy in the medical ICU. N Engl J Med 354:449-461.
  217. Van den Berghe GH. 2004. Role of intravenous insulin therapy in critically ill patients. Endocr Pract 10(Suppl 2):17-20.
  218. Van der Poll T, Levi M, Braxton CC, et al. 1998. Parenteral nutrition facilitates activation of coagulation but not fibrinolysis during human endotoxemia. J Infect Dis 177:793-795.
  219. Venkataraman, R, Fink MP. 2002. Mechanisms responsible for intestinal barrier dysfunction in critical illness, pp 282-300. In Evans TW, Fink MP (eds): Mechanisms of organ dysfunction in critical illness, ed 1. Springer, New York. Update in intensive care medicine.
  220. Vincent JL, Angus DC, Artigas A, et al. 2003. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med 31:834-840.
  221. Vincent JL, Bernard GR, Beale R, et al. 2005. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med 33:2266-2277.
  222. Vincent JL, De Backer D. 2005. Microvascular dysfunction as a cause of organ dysfunction in severe sepsis. Crit Care 9(Suppl 4):S9-S12.
  223. Vincent JL, Spapen H, Bakker J, et al. 2000. Phase II multicenter clinical study of the platelet-activating factor receptor antagonist BB-882 in the treatment of sepsis. Crit Care Med 28:638-642.
  224. Vincent JL, Sun Q, Dubois MJ. 2002. Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin Infect Dis 34:1084-1093.
  225. Vodovotz Y, Liu S, McCloskey C, et al. 2001. The hepatocyte as a microbial product-responsive cell. J Endotoxin Res 7:365-373.
  226. Waddell LS, Brady CA, Drobatz KJ. 2002. Risk factors, prognostic indicators, and outcome of pyothorax in cats: 80 cases (1986-1999). J Am Vet Med Assoc 221:819-824.
  227. Waddell LS, Brown AJ. 2009. Hemodynamic monitoring pp 859-864. In Silverstein DC, Hopper K (eds): Small animal critical care medicine. Saunders Elsevier, St Louis.
  228. Waeschle RM, Moerer O, Hilgers R, et al. 2008. The impact of the severity of sepsis on the risk of hypoglycaemia and glycaemic variability. Crit Care 12:R129.
  229. Walport MJ. 2001. Complement—first of two parts. N England J Med 344:1058-1066.
  230. Wan L, Bellomo R, Di Giantomasso D, et al. 2003. The pathogenesis of septic acute renal failure. Curr Opin Crit Care 9:496-502.
  231. Wang H, Ward MF, Sama AE, et al. 2009. Novel HMGB1-inhibiting therapeutic agents for experimental sepsis. Shock 32:348-357.
  232. Ware LB. 2006. Pathophysiology of acute lung injury and the acute respiratory distress syndrome. Semin Respir Crit Care Med 27:337-349.
  233. Warren BL, Eid A, Singer P, et al. 2001. Caring for the critically ill patient: high-dose anti-thrombin III in severe sepsis: a randomized, controlled trial. JAMA 286:1869-1878.
  234. Weiss DJ, Krehbiel JD, Lund JE. 1983. Studies of the pathogenesis of anemia of inflammation: mechanism of impaired erythropoiesis. Am J Vet Res 44:1832-1835.
  235. Weiss DJ, McClay CB. 1988. Studies on the pathogenesis of the erythrocyte destruction associated with the anemia of inflammatory disease. Vet Clin Pathol 17:90-93.
  236. Weiss DJ, Rashid J. 1998. The sepsis-coagulant axis: a review. J Vet Intern Med 12:317-324.
  237. Weiss DJ, Welle M, Mortiz A, Walcheck B. 2004. Evaluation of leukocyte cell surface markers in dogs with septic and nonseptic inflammatory diseases. Am J Vet Res 65:59-63.
  238. Wheeler DS, Zingarelli B, Wheeler WJ, et al. 2009. Novel pharmacologic approaches to the management of sepsis: targeting the host inflammatory response. Recent Patents Inflamm Allergy Drug Discov 3:96-112.
  239. Wiener RS, Wiener DC, Larson RJ. 2008. Benefits and risks of tight glucose control in critically ill adults: a meta-analysis. JAMA 300:933-944.
  240. Wilkins PA, Otto CM, Baumgardner JE, et al. 2007. Acute lung injury and acute respiratory distress syndromes in veterinary medicine: consensus definitions: The Dorothy Russell Havemeyer Working Group on ALI and ARDS in veterinary medicine. J Vet Emerg Crit Care 17:333-339.
  241. 229a. Wiwanitkit V. 2010. C-reactive protein in sepsis. J Vet Emerg Crit Care 20:1.
  242. Yang H, Ochani M, Li J, et al. 2004. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA 101:296-301.
  243. Zanotti-Cavazzoni SL, Hollenberg SM. 2009. Cardiac dysfunction in severe sepsis and septic shock. Curr Opin Crit Care 15:392-397.
  244. Zenni GC, McLane MP, Law WR, et al. 1992. Hepatic insulin resistance during chronic hyperdynamic sepsis. Circ Shock 37:198-208.